President Joe Biden has proposed expansions to the Inflation Reduction Act, including an increase in the annual number of prescription drugs that would be subject to price negotiations to 50, up from 20.
Tag Archive for: patient access
The company said its new program will dramatically decrease costs at the pharmacy counter for patients, including those who are uninsured or underinsured.
The company expects to reach 90% of its target for integrated delivery networks (IDNs) used to administer the drug in the U.S. in the fiscal year ending this month, its CEO stated.
Walgreens said it expected to begin dispensing the pills within a week, in select locations in New York, Pennsylvania, Massachusetts, California, and Illinois. CVS will begin filling prescriptions for the medication in Massachusetts and Rhode Island in the weeks ahead and expand to additional states, where allowed by law, on a rolling basis.
We at Med Ad News don’t claim to know all the questions. So we challenged our contributors to come up with their own questions and answer them.
Recent headlines are sounding alarm bells over the highest jump in healthcare costs in a decade. The impact has the potential to cause disruptions across key market access channels: employers, health plans, and pharmacy benefit managers.
The Biden administration is sending drugmakers opening offers for the U.S. Medicare program’s first ever price negotiations on Thursday, the White House said in a statement.
The Inflation Reduction Act’s Drug Price Negotiation Program will erode only a small portion of global biopharma revenues and is unlikely to cause significant cuts to research and development, find researchers.
Ahead of a Jan. 31 vote, Senate health committee chair Sen. Bernie Sanders on Thursday said he has the votes needed to subpoena the CEOs of Johnson & Johnson and Merck to testify on drug pricing.
How pharma companies can communicate effectively in today’s evolving marketplace and why it is the right time to embrace our humanity when engaging various stakeholders along the product, patient, and reimbursement/coverage journeys.
